Literature DB >> 3782862

Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma.

T Krieg, I Langer, H Gerstmeier, J Keller, H Mensing, G Goerz, R Timpl.   

Abstract

Sera from 101 patients with progressive systemic scleroderma were analyzed for circulating aminopropeptides of type III collagen using a radioimmunoassay which measures the intact and degraded forms (Fab assay). About 41% of the patients were found to have values above the normal range. A good correlation was observed between elevated levels of aminopropeptides and the degree of involvement of the skin and internal organs in the patients. Most patients (89%) with an active progression of the disease but not those in a stationary phase showed increased serum levels of aminopropeptides. Treatment with corticosteroids apparently normalized the levels of aminopropeptides. Only minor changes were observed with an antibody-based radioimmunoassay which measures primarily the intact form of the aminopropeptide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782862     DOI: 10.1111/1523-1747.ep12459865

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  [Laboratory diagnostics for systemic sclerosis].

Authors:  R Mierau; A Roers; E Genth
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

2.  Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.

Authors:  N G Guseva; N V Anikina; R Myllylä; L Risteli; J Risteli; J V Chochlova; K I Kivirikko; V A Nassonova
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

3.  Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma.

Authors:  S Majewski; A Skiendzielewska; B Makieła; S Jablońska; M Błaszczyk
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

4.  Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.

Authors:  K Kikuchi; H Ihn; S Sato; A Igarashi; Y Soma; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

Review 6.  Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases.

Authors:  Helena Kuivaniemi; Gerard Tromp
Journal:  Gene       Date:  2019-05-07       Impact factor: 3.688

7.  Serum markers of collagen synthesis and degradation in skin diseases. Altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment.

Authors:  P Autio; J Risteli; U Kiistala; L Risteli; J Karvonen; A Oikarinen
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

8.  Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma.

Authors:  B Eckes; C Mauch; G Hüppe; T Krieg
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.